Methotrexate and injectable tumor necrosis factor-α inhibitor adherence and persistence in children with rheumatic diseases

Journal of Rheumatology

Volumn 40, Issue 1, 2013, Pages 80-86

  Ringold, Sarah ^a   Grant, Shannon ^b   Girdish, Charmaine ^e   Wallace, Carol A ^c   Sullivan, Sean D ^d  

^a SEATTLE CHILDREN S HOSPITAL   (United States)

^b Axio Research LLC   (United States)

^c Rheumatology and Infectious Diseases   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e CVS Caremark   (United States)

Author keywords

Methotrexate; Patient compliance; Pediatric rheumatic diseases; Tumor necrosis factor inhibitor

Indexed keywords

ADALIMUMAB; ETANERCEPT; METHOTREXATE;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; CHILD; DRUG EFFICACY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; RHEUMATIC DISEASE; SCHOOL CHILD; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOGLOBULIN G; INFANT; INJECTIONS; MEDICATION ADHERENCE; METHOTREXATE; RECEPTORS, TUMOR NECROSIS FACTOR; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84871915633     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120753     Document Type: Article

References (31)

1. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97. (Pubitemid 41127293)
2. Berg JS, Dischler J, Wagner DJ, Raia JJ, Palmer-Shevlin N. Medication compliance: A healthcare problem. Ann Pharmacother 1993;9 Suppl:S1-24.
3. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-7. (Pubitemid 351160875)
4. Sacks JJ, Helmick CG, Luo YH, Ilowite NT, Bowyer S. Prevalence of and annual ambulatory health care visits for pediatric arthritis and other rheumatologic conditions in the United States in 2001-2004. Arthritis Rheum 2007;57:1439-45. (Pubitemid 350308842)
5. Tebbi CK. Treatment compliance in childhood and adolescence. Cancer 1993;71 Suppl:3441-9. (Pubitemid 23148540)
6. Friedman IM, Litt IF, King DR, Henson R, Holtzman D, Halverson D, et al. Compliance with anticonvulsant therapy by epileptic youth. Relationships to psychosocial aspects of adolescent development. J Adolesc Health Care 1986;7:12-7. (Pubitemid 16168496)
7. Asadi-Pooya AA. Drug compliance of children and adolescents with epilepsy. Seizure 2005;14:393-5. (Pubitemid 41200491)
8. Shemesh E, Shneider BL, Savitzky JK, Arnott L, Gondolesi GE, Krieger NR, et al. Medication adherence in pediatric and adolescent liver transplant recipients. Pediatrics 2004;113:825-32. (Pubitemid 38437390)
9. Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O'Neil KM, Zeft AS, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 2012;64:2012-21.
10. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 2011;63:465-82.
11. Beukelman T, Xie F, Curtis JR. Usage of TNF± inhibitors for the treatment of juvenile idiopathic arthritis: data from a national U.S. administrative claims database [abstract]. Arthritis Rheum 2010;62 Suppl:S100.
12. Diaz-Llopis M, Salom D, Garcia-de-Vicuna C, Cordero-Coma M, Ortega G, Ortego N, et al. Treatment of refractory uveitis with adalimumab: A prospective multicenter study of 131 patients. Ophthalmology 2012;119:1575-81.
13. Minden K, Niewerth M, Zink A, Seipelt E, Foeldvari I, Girschick H, et al. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology 2012;51:1407-15.
14. Ramos-Casals M, Brito-Zeron P, Munoz S, Soto MJ. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine 2008;87:345-64.
15. Litt IF, Cuskey WR. Compliance with salicylate therapy in adolescents with juvenile rheumatoid arthritis. Am J Dis Child 1981;135:434-6. (Pubitemid 11120796)
16. Pelajo CF, Sgarlat CM, Lopez-Benitez JM, Oliveira SK, Rodrigues MC, Sztajnbok FR, et al. Adherence to MTX in juvenile idiopathic arthritis. Rheumatol Int 2012;32:497-500.
17. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: Optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 2009;25:2303-10.
18. Rhee H, Belyea MJ, Brasch J. Family support and asthma outcomes in adolescents: Barriers to adherence as a mediator. J Adolesc Health 2010;47:472-8.
19. McQuaid EL, Kopel SJ, Klein RB, Fritz GK. Medication adherence in pediatric asthma: Reasoning, responsibility, and behavior. J Pediatr Psychol 2003;28:323-33. (Pubitemid 36750456)
20. Ray WA. Evaluating medication effects outside of clinical trials: New-user designs. Am J Epidemiol 2003;158:915-20. (Pubitemid 37323253)
21. Dunbar-Jacob J, Mortimer-Stephens MK. Treatment adherence in chronic disease. J Clin Epidemiol 2001;54 Suppl 1:S57-60. (Pubitemid 34013691)
22. Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: Three decades of research. A comprehensive review. J Clin Pharm Ther 2001;26:331-42. (Pubitemid 32989555)
23. Feldman DE, De Civita M, Dobkin PL, Malleson PN, Meshefedjian G, Duffy CM. Effects of adherence to treatment on short-term outcomes in children with juvenile idiopathic arthritis. Arthritis Rheum 2007;57:905-12. (Pubitemid 47237315)
24. April KT, Feldman DE, Zunzunegui MV, Duffy CM. Association between perceived treatment adherence and health-related quality of life in children with juvenile idiopathic arthritis: Perspectives of both parents and children. Patient Prefer Adherence 2008;2:121-8.
25. Rapoff MA. Compliance with treatment regimens for pediatric rheumatic diseases. Arthritis Care Res 1989;2:S40-7. (Pubitemid 20074311)
26. Mattke S, Martorell F, Hong SY, Sharma P, Cuellar A, Lurie N. Anti-inflammatory medication adherence and cost and utilization of asthma care in a commercially insured population. J Asthma 2010;47:323-9.
27. Barner JC, Khoza S, Oladapo A. ADHD medication use, adherence, persistence and cost among Texas Medicaid children. Curr Med Res Opin 2011;27 Suppl:13-22.
28. Sanchez RJ, Crismon ML, Barner JC, Bettinger T, Wilson JP. Assessment of adherence measures with different stimulants among children and adolescents. Pharmacotherapy 2005; 25:909-17. (Pubitemid 40917923)
29. Grijalva CG, Kaltenbach L, Arbogast PG, Mitchel EF Jr, Griffin MR. Adherence to disease-modifying antirheumatic drugs and the effects of exposure misclassification on the risk of hospital admission. Arthritis Care Res 2010;62:730-4.
30. Borah BJ, Huang X, Zarotsky V, Globe D. Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs. Curr Med Res Opin 2009;25:1365-77.
31. Rapoff MA, Belmont JM, Lindsley CB, Olson NY. Electronically monitored adherence to medications by newly diagnosed patients with juvenile rheumatoid arthritis. Arthritis Rheum 2005; 53:905-10. (Pubitemid 41811132)